CD55 and neoplasm: In summary, this study uncovered a new role of complement in B-cell-dependent anti-tumor immunity and indicated that CD55 induced chemo-resistance by impeding the induction of ICOSL+ B cells and could thus be a potential therapeutic target to enhance the efficacy of immunogenic chemotherapy.